A Phase 3 interventional study of Apraglutide in Short Bowel Syndrome, sponsored by VectivBio AG. Active, not recruiting at 66 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-02.
Sponsored by VectivBio AG (part of Ironwood Pharmaceuticals, Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Short Bowel Syndrome with a site in United States — 11 open to participants now, 15 under way, 4 of them phase 3. Short Bowel Syndrome · United States.
Among the 80 studies in Short Bowel Syndrome with a site in United States, this one is the 3rd largest by enrollment of the 66 interventional ones that give a count, is one of 7 that started in 2021, is one of 20 in phase 3, reaches primary completion later than 5 of the 14 other live ones, and was the 68th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →11 of the 80 studies in Short Bowel Syndrome with a site in United States are open now. Recruiting first, the newest first:
VectivBio AG · Sites in United States, Argentina, Australia and 19 more countries
Ages 18+
Zealand Pharma · Sites in United States, Austria, Belgium and 11 more countries
Ages 18–90
Eclipse Regenesis, Inc. · Sites in United States
Ages 3 mo–65 yrs
Children's Hospital of Philadelphia · Sites in United States
Ages 4 mo–18 yrs · Healthy volunteers
Hanmi Pharmaceutical Company Limited · Sites in United States, Belgium, Denmark and 5 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 23 · Phase 4 7
First in 1996; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 158 is above the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 23 across the 66 interventional studies, 143 across the 10 observational. Of the 52 that completed or were terminated, 29 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 80 have an industry lead sponsor. The 10 most frequent:
This study is registered under VectivBio AG, one of the names counted as Ironwood Pharmaceuticals, Inc.. Under that name alone:
VectivBio AG is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
Ironwood Pharmaceuticals, Inc. has 4 studies filed under Short Bowel Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Short Bowel Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05018286Phase 3VectivBio AGOpen-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. | 2027-10-30 |
| NCT06240065University of Texas Southwestern Medical CenterSuccessful Fiber Food Introduction in Short Bowel Syndrome | 2027-04 |
| NCT03530852Boston Children's HospitalA 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB | 2027-06-30 |
| NCT05432648Children's Hospital of PhiladelphiaFiber Food Introduction in Pediatric Short Bowel Syndrome | 2027-08-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 80 studies in Short Bowel Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the trial is to assess long-term safety and tolerability of apraglutide in subjects with SBS-IF.
This is an international, multicenter, open label extension trial to collect further safety, tolerability, efficacy, durability, and clinical outcomes of apraglutide once weekly adminstration, for up to 208 weeks or until apraglutide is commercially available in the country, whichever comes first. Eligible subjects would be those who were trial subjects of TA799-007 or TA799-013 trials.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Peptide analogue of Glucagon-like Peptide 2 (GLP-2)
Drug: Apraglutide
Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2
Adverse events (AE)
System organ class, frequency and severity
Time frame: From baseline to week 208
Clinical chemistry
Clinical Chemistry panel of analytes will be examined for clinically significant changes.
Time frame: From baseline to week 208
Hematology
Hematology panel of analytes will be examined for clinically significant changes.
Time frame: From baseline to week 208
Hemostasis
Hemostasis INR will be examined for clinically significant changes.
Time frame: From baseline to week 104
Urinalysis
Urinanalysis panel of analytes will be examined for clinically significant changes.
Time frame: From baseline to week 208
Occurrence of clinically relevant changes in vital signs
* Systolic and diastolic blood pressure in mmHg will be examined for clinically significant changes. * Heart rate in Beats per Minute (BPM) will be examined for clinically significant changes.
Time frame: From baseline to week 208
Occurrence of clinically relevant changes in electrocardiogram
ECG; intervals and rhythm
Time frame: From baseline to week 208
Change from baseline in PS volume
Time frame: From baseline to week 208
Change from baseline in PS frequency
Change in PS days/week from baseline to week 104
Time frame: From baseline to week 208
Clinically significant changes in PS total energy
Units: kcal
Time frame: From baseline to week 208
Change from baseline in PS infusion time
Time frame: From baseline to week 208
Percentage of subjects reaching enteral autonomy
Time frame: From baseline to week 104
Change from baseline in body weight
Units: kg
Time frame: From baseline to week 104
Change from baseline on the Patient Global Impression of Severity (PGIS)
Time frame: From baseline to week 104
Change from baseline on the Pittsburgh Sleep Quality Inventory (PSQI)
Time frame: From baseline to week 208
Change from baseline on the Patient Global Impression of Change (PGIC)
Time frame: From baseline to week 208
Changes from baseline on Patient Global Impression of Treatment Satisfaction (PGI-TS)
Time frame: From baseline to week 208
Changes from baseline on Patient Global Impression of Satisfaction with Parenteral Support (PGI-SPS)
Time frame: From baseline to week 208
Changes from baseline on Patient Global Impression of Parenteral Support Impact (PGI-PSI)
Time frame: From baseline to week 208
Change from baseline on the Short Form (36) Health Survey (SF-36)
Time frame: From baseline to week 208
Change from baseline on the EuroQoL-5 dimension -5 level survey (EQ-5D-5L)
Time frame: From baseline to week 208
Started Jul 2021 (actual). Primary completion is estimated for Oct 2027, 75 months after the start.
Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 75 months is above that.
Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apraglutide